Biosimilar Bevacizumab Market to grow at a CAGR of 9.02% during 2025 to 2035; Driven by Rising Incidence of Cancer and Increasing Adoption of Cost-Effective Biosimilars

Biosimilar Bevacizumab Market Highlights

Global Biosimilar Bevacizumab Market Size was valued at USD 1.814 Billion in 2024 & the market is projected to grow from USD 1.978 Billion in 2025 to USD 4.691 Billion by 2035, registering a CAGR of 9.02% during the forecast period 2025–2035.

The growing awareness and acceptance among healthcare professionals, especially in developed and developing economies, will further create lucrative market growth opportunities. Healthcare professionals, including physicians and pharmacists, increasingly recognize the therapeutic equivalence and cost-effectiveness of biosimilar bevacizumab compared to the reference product. Additionally, ongoing education and training initiatives further enhance healthcare professionals' understanding and utilization of biosimilars, reinforcing their role in driving market expansion.

MRFR recognizes the following companies as the key players in the global Biosimilar bevacizumab market— Amgen, AryoGen Pharmed, Biothera, Boehringer Ingelheim, Centus Biotherapeutics, Henlius Biotech, Innovent Biologics, Mylan, mAbxience, Outlook Therapeutics, Pfizer, Prestige Biopharma, Roche, Samsung Bio and TOT Biopharm.

Segment Analysis

The global biosimilar bevacizumab market has been segmented based on product, application, and distribution channel.

The market is segmented by product into avastin, mvasi, zirabev, aybintio, and other clinical trial products. The avastin segment held the largest market share in 2023. The growing incidence of cancer, the need for more accessible treatment alternatives, and the branded medicine patent expirations are the main factors driving the category growth. Initiatives encouraging their usage in conjunction with regulatory approvals for biosimilars drive further market expansion. These dynamics change the game, making life-saving treatments more accessible and affordable for people all around the world.

Based on application, the global biosimilar bevacizumab market has been segmented into colorectal cancer, non-small cell lung cancer, glioblastoma, renal cell carcinoma, cervical cancer, and ovarian cancer. The colorectal cancer manufacturing segment was expected to hold the largest market share in 2023. The market is growing because colorectal cancer is becoming more common and because people need more accessible treatment alternatives. Furthermore, reference biologics' patent expirations open the door for biosimilar entrants, increasing competition and bringing down costs.

Based on distribution channels, the global biosimilar bevacizumab market has been segmented into hospital pharmacies, online pharmacies, and others. The hospital pharmacy segment was expected to hold the largest market share in 2023. Hospitals are compelled to incorporate these substitutes into their formularies due to the biosimilar Bevacizumab market's notable drivers of accessibility and cost-effectiveness. Hospitals are looking for biosimilars as practical substitutes for pricey original biologics, improving affordability and patient access to necessary therapies, in response to mounting demand to reduce healthcare costs without sacrificing patient care.

Regional Analysis

The global biosimilar bevacizumab market, based on region, has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America consists of the US and Canada. The European biosimilar bevacizumab market comprises Germany, France, the UK, Italy, Spain, and the rest of Europe. The biosimilar bevacizumab market in Asia-Pacific has been segmented into China, India, Japan, Australia, South Korea, and the rest of Asia-Pacific. The rest of the World's biosimilar bevacizumab market comprises the Middle East, Africa, and Latin America.

The North American regional sector maintained the largest market share for biosimilar bevacizumab. The region's well-established healthcare infrastructure, favorable regulatory environment, and rising prevalence of cancer, coupled with initiatives promoting biosimilar adoption, further propel market growth. Enhanced research and development efforts by key market players to introduce innovative biosimilar products also bolster market dynamics in North America, positioning it as a prominent region in the biosimilar bevacizumab market landscape.

Moreover, the European market has been persistently growing over the forecast period. The demand for biosimilar bevacizumab is driven by a favorable regulatory environment supporting biosimilar approvals, rising healthcare expenditure, and growing awareness among healthcare professionals and patients. Collaborations between key market players and healthcare organizations contribute to enhanced accessibility and affordability of biosimilar bevacizumab across European countries, fostering its adoption in clinical practice.

Additionally, due to the increasing prevalence of cancer, rising demand for affordable treatment options, favorable regulatory environment, and growing emphasis on healthcare cost containment, Asia Pacific is anticipated to experience the quickest growth over the forecast period. Additionally, collaborations between pharmaceutical companies and governments to promote biosimilar adoption further propel market growth, fostering accessibility to vital cancer treatments like bevacizumab in Asia-Pacific.

Furthermore, the rest of the World's biosimilar bevacizumab market is divided into the Middle East, Africa, and Latin America. This growth is attributed to the increasing demand for cost-effective cancer treatments, favorable government initiatives promoting biosimilar adoption, the rising prevalence of cancer, advancements in biotechnology and robust R&D efforts, regulatory approvals, and patent expirations further stimulate market expansion.

Key Findings of the Study

• North America accounted for over 44.10% of global Biosimilar Bevacizumab Market revenue in 2024, maintaining regional leadership.


• Europe generated USD 0.5442 billion in revenue during 2024, representing approximately 30% of the global market.


• Avastin represented approximately 58% of market revenue in 2024, supported by strong physician confidence and established oncology applications.


• Hospital Pharmacies accounted for nearly 69% market share in 2024, remaining the primary distribution channel for oncology biologics.